Radiotherapy After mastectomy: New Trial Challenges Standard Practice for Intermediate-Risk Patients
Table of Contents
For decades,radiotherapy following mastectomy has been a standard practice aimed at minimizing the risk of local cancer recurrence,particularly in cases involving larger tumors or lymph node involvement. However, evolving treatments and a growing emphasis on patient-centered care have prompted a re-evaluation of this long-held protocol. Recent findings from a major international trial, published in the New England Journal of Medicine, are now prompting clinicians to question the automatic application of radiotherapy for patients with intermediate-risk breast cancer.
The Meaning of the Question:
In France alone, approximately 60,000 new breast cancer cases are diagnosed annually, leading to 20,000-22,000 mastectomies. While radiotherapy post-mastectomy has historically been clearly indicated for high-risk cases, its necessity for intermediate-risk patients has been a subject of ongoing debate. The SUPREMO trial offers compelling evidence that may significantly alter current practices.
SUPREMO Trial: Key Findings and Implications
The SUPREMO trial, conducted by the University of Edinburgh in the United kingdom, followed nearly 1,600 patients across 17 countries for approximately ten years. Participants, all of whom had undergone mastectomy and axillary dissection and were receiving modern systemic anticancer therapies, were categorized as intermediate risk – defined by either one to three lymph node involvement or other aggressive tumor characteristics. Patients were randomly assigned to receive chest wall irradiation or to forego radiotherapy.
the results revealed a striking similarity in overall survival rates between the two groups: 81.4% for women who received radiotherapy versus 81.9% for those who did not. Furthermore, no meaningful difference was observed in disease-free survival or the incidence of cancer spread. While radiotherapy demonstrated a relative reduction in local recurrence of approximately 45%, the absolute difference between the groups was a modest 2 percentage points.
According to Professor Ian Kunkler, of the Institute of Genetics and Cancer at the University of Edinburgh, “The SUPREMO trial provides no evidence to justify continuing radiotherapy to the chest wall in most intermediate-risk breast cancer patients who have undergone mastectomy, if they are also treated with modern anticancer drugs.”
why the Shift? The Impact of Modern Systemic Therapies
The diminishing benefit of radiotherapy in intermediate-risk cases can be largely attributed to advancements in systemic treatments. Modern chemotherapy, hormonal therapy, and targeted therapies have dramatically reduced the overall risk of relapse, lessening the potential impact of radiotherapy on survival outcomes.
While a benefit on local recurrence remains, the absolute reduction is small, prompting patients to carefully weigh this benefit against the potential adverse effects of radiation. These side effects can include skin reactions, cardiac or pulmonary toxicities, and a negative impact on quality of life, particularly for those considering breast reconstruction.
Professor John Simpson, Director of the MRC-NIHR Effectiveness and Mechanisms Evaluation (EME) programme, emphasized the importance of the trial, stating, “It is fantastic that this long-term UK-led international clinical trial has provided high-quality evidence that has been lacking in this important clinical area. These results could enable patients to avoid unnecessary treatments, leading to more effective and efficient use of health and care resources.”
Future implications: Individualized Treatment Decisions
The SUPREMO trial dose not advocate for a complete abandonment of post-mastectomy radiotherapy. It remains critically critically important for patients at high risk of recurrence, such as those with large tumors or extensive lymph node involvement. However, the findings strongly support a more individualized approach to treatment decisions for intermediate-risk cancers.
Moving forward, clinicians will likely consider a more complete assessment of each patient’s unique profile, including tumor characteristics, biological markers, and, crucially, patient preferences. In many cases of intermediate-risk breast cancer, particularly in women receiving modern systemic therapies, omitting radiotherapy may be a safe and appropriate option.
This trial represents a significant step towards optimizing breast cancer treatment, prioritizing both efficacy and quality of life for patients undergoing mastectomy. Further research and ongoing evaluation of evolving practices will be essential to refine these recommendations and ensure the best possible outcomes for all individuals affected by this disease.